FierceBiotech· @FierceBiotech · X·· 9 天前精选AI 评分62
AI 导读
在武田的发作性睡病治疗药物 Orzeyful 成为首个获批的食欲素激动剂之后，Alkermes 公布了该类药物用于 ADHD 的开创性数据，试图将这一热门药物类别从睡眠障碍拓展到更广泛的患者人群。相关数据发布在 Fierce Biotech 的报道中（https://www.fiercebiotech.com/biotech/pioneering-adhd-data-alkermes-eyes-orexin-agonist-potential-company-changer）。
推荐理由
武田食欲素激动剂获批后，Alkermes 公布将该类药物拓展至睡眠障碍以外人群的数据，可观察这一新靶点的适应症外延方向。
正文
Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of sleep disorders and into broader patient populations. https://www.fiercebiotech.com/biotech/pioneering-adhd-data-alkermes-eyes-orexin-agonist-potential-company-changer
来源：FierceBiotech · x.com